Results 121 to 130 of about 10,841,366 (345)

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

Nature Network Boston, 2020
D. Braun, Yue Hou, Z. Bakouny, M. Ficial, Miriam Sant’ Angelo, J. Forman, P. Ross-Macdonald, Ashton C. Berger, O. Jegede, L. Elagina, J. Steinharter, Maxine Sun, M. Wind-Rotolo, Jean-Christophe Pignon, A. Cherniack, Lee T Lichtenstein, D. Neuberg, P. Catalano, G. Freeman, A. Sharpe, D. McDermott, E. V. Van Allen, S. Signoretti, Catherine J. Wu, S. Shukla, T. Choueiri   +25 more
semanticscholar   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

IN VITRO STUDIES OF MAMMALIAN SOMATIC CELL VARIATION [PDF]

, 1963
Howard M. Cann, Leonard A. Herzenberg
openalex   +1 more source

Hybrid Somatic Cells

Scientific American, 1969
Mary C. Weiss, Boris Ephrussi
openaire   +4 more sources

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

Embryonic hybrid cells: a powerful tool for studying pluripotency and reprogramming of the differentiated cell chromosomes

Anais da Academia Brasileira de Ciências, 2001
The properties of embryonic hybrid cells obtained by fusion of embryonic stem (ES) or teratocarcinoma (TC) cells with differentiated cells are reviewed. Usually, ES-somatic or TC-somatic hybrids retain pluripotent capacity at high levels quite comparable
SEROV OLEG, MATVEEVA NATALIA, KUZNETSOV SERGEY, KAFTANOVSKAYA ELENA, MITTMANN JOSANE   +4 more
doaj  

The development of aneuploidy in somatic cells of experimentally produced triploid larches [PDF]

, 1966
Z. M. Illies
openalex   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Correlation Between the Surface Charge Density of Whole Cells and Electrophoretic Movement of Isolated Somatic Antigen of Rhizobium trifolii [PDF]

, 1969
Beverley A. Humphrey, J. M. Vincent
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source